In a report released today, Jonathan Block from Stifel Nicolaus maintained a Buy rating on Trupanion (NYSE: TRUP), with a price target of $40. The company’s shares closed yesterday at $39.68, close to its 52-week high of $42.39.
According to TipRanks.com, Block is a 5-star analyst with an average return of 23.3% and a 76.0% success rate. Block covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Idexx Laboratories, and Align Tech.
Trupanion has an analyst consensus of Moderate Buy, with a price target consensus of $40.
See today’s analyst top recommended stocks >>
The company has a one-year high of $42.39 and a one-year low of $20.52. Currently, Trupanion has an average volume of 332.3K.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Trupanion, Inc. engages in the provision of medical insurance for cats and dogs. It operates through the Subscription Business and Other Business segments. The Subscription Business segment involves in the monthly subscriptions of pet medical insurance.
